03Feb 2025
REVERSE Trial Assesses Rivaroxaban for BPV Surgery Anticoagulation

REVERSE Trial Assesses Rivaroxaban for BPV Surgery Anticoagulation

The REVERSE trial evaluated rivaroxaban versus warfarin for anticoagulation in 250 patients after bioprosthetic valve surgery. This multicenter, randomized trial assesses a six-month treatment period, with primary outcomes including all-cause death, major cardiovascular events, and major bleeding. Safety is measured by ISTH-defined bleeding events.

  • #cardiology

Like

Save

Share